Symbols / CLNN Stock $6.50 +0.00% Clene Inc.

Consumer Defensive • Packaged Foods • United States • NCM
CLNN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Consumer Defensive
Industry Packaged Foods
CEO Mr. Robert Etherington MBA
Exch · Country NCM · United States
Market Cap 76.56M
Enterprise Value 93.04M
Income -26.17M
Sales 200.00K
FCF (ttm) -10.14M
Book/sh -1.62
Cash/sh 0.44
Employees 76
Insider 10d —
IPO Oct 18, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.33
PEG —
P/S 382.79
P/B -4.01
P/C —
EV/EBITDA -4.31
EV/Sales 465.21
Quick Ratio 0.54
Current Ratio 0.83
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -2.66
EPS next Y -1.95
EPS Growth —
Revenue Growth -15.40%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-12
Earnings (prior) 2026-03-12
ROA -63.46%
ROE —
ROIC —
Gross Margin 78.50%
Oper. Margin -97.34%
Profit Margin 0.00%
Shs Outstand 11.78M
Shs Float 8.56M
Insider Own 24.56%
Instit Own 18.86%
Short Float 10.23%
Short Ratio 10.44
Short Interest 875.03K
52W High 13.50
vs 52W High -51.85%
52W Low 2.28
vs 52W Low 185.09%
Beta 0.89
Impl. Vol. —
Rel Volume 0.33
Avg Volume 490.64K
Volume 160.48K
Target (mean) $30.67
Tgt Median $30.00
Tgt Low $20.00
Tgt High $50.00
# Analysts 6
Recom Strong_buy
Prev Close $6.50
Price $6.50
Change 0.00%
About

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$30.67
Mean price target
2. Current target
$6.50
Latest analyst target
3. DCF / Fair value
$-15.49
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.50
Low
$20.00
High
$50.00
Mean
$30.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-04 reit HC Wainwright & Co. Buy → Buy $31
2026-05-04 main D. Boral Capital Buy → Buy $23
2026-03-13 main Canaccord Genuity Buy → Buy $48
2026-03-12 main D. Boral Capital Buy → Buy $23
2026-01-09 main D. Boral Capital Buy → Buy $23
2025-12-10 main D. Boral Capital Buy → Buy $23
2025-12-03 main D. Boral Capital Buy → Buy $23
2025-11-17 main D. Boral Capital Buy → Buy $23
2025-09-25 main D. Boral Capital Buy → Buy $23
2025-09-10 main Benchmark Buy → Buy $31
2025-08-21 main D. Boral Capital Buy → Buy $23
2025-08-18 main Canaccord Genuity Buy → Buy $48
2025-08-14 main D. Boral Capital Buy → Buy $23
2025-07-18 main D. Boral Capital Buy → Buy $23
2025-06-30 main D. Boral Capital Buy → Buy $23
2025-05-08 main Benchmark Buy → Buy $33
2025-05-08 main D. Boral Capital Buy → Buy $23
2025-04-23 init Jones Trading — → Buy $30
2025-04-08 main D. Boral Capital Buy → Buy $23
2025-04-08 reit HC Wainwright & Co. Buy → Buy $31
News
RSS: Latest CLNN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-04 UGWUMBA CHIDOZIE Beneficial Owner of more than 10% of a Class of Security — 78,679 $6.01 $530,439
2026-04-30 UGWUMBA CHIDOZIE Beneficial Owner of more than 10% of a Class of Security — 19,497 $5.63 $112,779
2026-04-21 UGWUMBA CHIDOZIE Beneficial Owner of more than 10% of a Class of Security — 65,663 $6.12 $403,084
2026-04-17 UGWUMBA CHIDOZIE Beneficial Owner of more than 10% of a Class of Security — 39,162 $6.40 $251,898
2026-04-02 UGWUMBA CHIDOZIE Beneficial Owner of more than 10% of a Class of Security — 24,925 $4.81 $119,889
2026-04-01 UGWUMBA CHIDOZIE Beneficial Owner of more than 10% of a Class of Security — 4,278 $4.97 $21,262
2026-03-31 UGWUMBA CHIDOZIE Beneficial Owner of more than 10% of a Class of Security — 100,997 $4.75 $494,012
2026-03-26 UGWUMBA CHIDOZIE Beneficial Owner of more than 10% of a Class of Security — 17,909 $5.40 $99,505
2026-02-03 UGWUMBA CHIDOZIE Beneficial Owner of more than 10% of a Class of Security — 5,559 $4.10 $22,792
2026-02-02 UGWUMBA CHIDOZIE Beneficial Owner of more than 10% of a Class of Security — 24,770 $4.04 $104,862
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.20
-41.52%
0.34
-47.71%
0.65
+38.27%
0.47
Operating Revenue
0.20
-41.52%
0.34
-47.71%
0.65
+38.27%
0.47
Cost Of Revenue
0.04
-38.57%
0.07
-42.15%
0.12
+365.38%
0.03
Reconciled Cost Of Revenue
0.04
-38.57%
0.07
-42.15%
0.12
+365.38%
0.03
Gross Profit
0.16
-42.28%
0.27
-48.97%
0.53
+19.24%
0.45
Operating Expense
21.97
-31.86%
32.25
-16.87%
38.79
-13.80%
45.00
Research And Development
14.01
-30.15%
20.06
-24.75%
26.66
-16.49%
31.92
Selling General And Administration
8.43
-32.16%
12.43
-3.17%
12.83
-20.60%
16.16
General And Administrative Expense
8.43
-32.16%
12.43
-3.17%
12.83
-20.60%
16.16
Salaries And Wages
6.27
-26.97%
8.58
-7.65%
9.29
-6.08%
9.90
Other Gand A
1.44
-52.47%
3.02
+55.24%
1.95
-32.22%
2.87
Other Operating Expenses
-0.61
-21.43%
-0.50
+47.66%
-0.96
+68.72%
-3.08
Total Expenses
22.02
-31.87%
32.32
-16.95%
38.91
-13.58%
45.03
Operating Income
-21.82
+31.77%
-31.98
+16.43%
-38.26
+14.13%
-44.56
Total Operating Income As Reported
-23.08
+30.25%
-33.09
+18.37%
-40.54
+16.26%
-48.41
EBITDA
-22.00
+34.71%
-33.69
+22.09%
-43.24
-68.89%
-25.60
Normalized EBITDA
-21.11
+35.00%
-32.48
+37.60%
-52.05
-18.15%
-44.05
Reconciled Depreciation
1.50
-9.12%
1.65
-3.52%
1.71
+67.32%
1.02
EBIT
-23.49
+33.52%
-35.34
+21.38%
-44.95
-68.83%
-26.62
Total Unusual Items
-0.89
+26.92%
-1.21
-113.75%
8.81
-52.27%
18.45
Total Unusual Items Excluding Goodwill
-0.89
+26.92%
-1.21
-113.75%
8.81
-52.27%
18.45
Special Income Charges
0.00
+100.00%
-0.13
-105.22%
2.47
-86.49%
18.28
Other Special Charges
—
0.21
—
-0.42
Restructuring And Mergern Acquisition
0.00
+100.00%
-0.09
+96.56%
-2.47
+86.17%
-17.86
Net Income
-26.17
+33.57%
-39.40
+20.41%
-49.50
-65.47%
-29.92
Pretax Income
-26.17
+33.57%
-39.40
+20.41%
-49.50
-65.47%
-29.92
Net Non Operating Interest Income Expense
-3.47
+12.32%
-3.96
+11.73%
-4.49
-16.70%
-3.84
Interest Expense Non Operating
2.68
-34.01%
4.06
-10.84%
4.56
+38.29%
3.30
Net Interest Income
-3.47
+12.32%
-3.96
+11.73%
-4.49
-16.70%
-3.84
Interest Expense
2.68
-34.01%
4.06
-10.84%
4.56
+38.29%
3.30
Interest Income Non Operating
0.22
-74.22%
0.86
-37.72%
1.39
+517.33%
0.23
Interest Income
0.22
-74.22%
0.86
-37.72%
1.39
+517.33%
0.23
Other Income Expense
-0.89
+74.47%
-3.47
+48.71%
-6.76
-136.56%
18.48
Other Non Operating Income Expenses
—
-2.25
+85.51%
-15.56
-48740.63%
0.03
Gain On Sale Of Security
-0.89
+18.21%
-1.08
-117.07%
6.34
+3649.70%
0.17
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-26.17
+33.57%
-39.40
+20.41%
-49.50
-65.47%
-29.92
Net Income From Continuing Operation Net Minority Interest
-26.17
+33.57%
-39.40
+20.41%
-49.50
-65.47%
-29.92
Net Income From Continuing And Discontinued Operation
-26.17
+33.57%
-39.40
+20.41%
-49.50
-65.47%
-29.92
Net Income Continuous Operations
-26.17
+33.57%
-39.40
+20.41%
-49.50
-65.47%
-29.92
Normalized Income
-25.29
+33.78%
-38.19
+34.51%
-58.31
-20.55%
-48.37
Net Income Common Stockholders
-26.17
+33.57%
-39.40
+20.41%
-49.50
-65.47%
-29.92
Diluted EPS
-2.65
+53.26%
-5.67
+39.87%
-9.43
-2.50%
-9.20
Basic EPS
-2.65
+53.26%
-5.67
+39.87%
-9.43
-2.50%
-9.20
Basic Average Shares
9.86
+41.77%
6.95
+32.54%
5.25
+60.94%
3.26
Diluted Average Shares
9.86
+41.77%
6.95
+32.54%
5.25
+60.94%
3.26
Diluted NI Availto Com Stockholders
-26.17
+33.57%
-39.40
+20.41%
-49.50
-65.47%
-29.92
Depreciation Amortization Depletion Income Statement
0.14
-45.86%
0.27
-0.37%
0.27
—
Depreciation And Amortization In Income Statement
0.14
-45.86%
0.27
-0.37%
0.27
—
Depreciation Income Statement
0.14
-45.86%
0.27
-0.37%
0.27
—
Insurance And Claims
0.72
-11.80%
0.82
-48.40%
1.59
-53.08%
3.40
Total Other Finance Cost
1.01
+33.11%
0.76
-42.22%
1.32
+70.38%
0.77
Line Item Trend 2023-12-31
Total Assets
52.34
Current Assets
38.85
Cash Cash Equivalents And Short Term Investments
35.00
Cash And Cash Equivalents
28.82
Cash Equivalents
25.00
Cash Financial
3.82
Other Short Term Investments
6.18
Receivables
1.34
Accounts Receivable
0.14
Other Receivables
—
Taxes Receivable
1.20
Inventory
0.04
Raw Materials
0.02
Finished Goods
0.01
Prepaid Assets
1.91
Other Current Assets
0.57
Total Non Current Assets
13.49
Net PPE
13.43
Gross PPE
20.32
Accumulated Depreciation
-6.89
Properties
0.00
Machinery Furniture Equipment
0.64
Construction In Progress
1.44
Other Properties
8.26
Leases
9.98
Other Non Current Assets
0.06
Total Liabilities Net Minority Interest
38.95
Current Liabilities
25.33
Payables And Accrued Expenses
2.67
Payables
1.50
Accounts Payable
1.50
Current Accrued Expenses
1.16
Pensionand Other Post Retirement Benefit Plans Current
2.12
Current Debt And Capital Lease Obligation
20.11
Current Debt
19.50
Other Current Borrowings
19.50
Current Capital Lease Obligation
0.60
Current Deferred Liabilities
0.44
Current Deferred Revenue
0.44
Total Non Current Liabilities Net Minority Interest
13.62
Long Term Debt And Capital Lease Obligation
12.05
Long Term Debt
7.15
Long Term Capital Lease Obligation
4.90
Other Non Current Liabilities
0.09
Stockholders Equity
13.39
Common Stock Equity
13.39
Capital Stock
0.00
Common Stock
0.00
Share Issued
6.42
Ordinary Shares Number
6.42
Treasury Shares Number
0.00
Additional Paid In Capital
255.91
Retained Earnings
-242.72
Gains Losses Not Affecting Retained Earnings
0.20
Other Equity Adjustments
0.20
Total Equity Gross Minority Interest
13.39
Total Capitalization
20.54
Working Capital
13.52
Invested Capital
40.05
Total Debt
32.16
Net Debt
—
Capital Lease Obligations
5.51
Net Tangible Assets
13.39
Tangible Book Value
13.39
Derivative Product Liabilities
1.48
Other Inventories
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-18.55
+13.04%
-21.33
+29.32%
-30.17
+22.66%
-39.01
Cash Flow From Continuing Operating Activities
-18.55
+13.04%
-21.33
+29.32%
-30.17
+22.66%
-39.01
Net Income From Continuing Operations
-26.17
+33.57%
-39.40
+20.41%
-49.50
-65.47%
-29.92
Depreciation Amortization Depletion
1.50
-9.12%
1.65
-3.52%
1.71
+67.32%
1.02
Depreciation
1.50
-9.12%
1.65
-3.52%
1.71
+67.32%
1.02
Depreciation And Amortization
1.50
-9.12%
1.65
-3.52%
1.71
+67.32%
1.02
Other Non Cash Items
2.22
-41.88%
3.82
-74.63%
15.04
+188.89%
-16.92
Stock Based Compensation
6.38
-19.75%
7.95
-12.77%
9.12
+7.10%
8.51
Operating Gains Losses
0.89
-38.92%
1.45
+122.87%
-6.34
-3694.61%
-0.17
Gain Loss On Investment Securities
0.89
-18.13%
1.08
+117.06%
-6.34
-3694.61%
-0.17
Gain Loss On Sale Of PPE
0.00
-100.00%
0.15
0.00
—
Change In Working Capital
-3.35
-204.42%
3.21
+1781.15%
-0.19
+87.60%
-1.54
Change In Receivables
0.06
-18.99%
0.08
+71.74%
0.05
+132.86%
-0.14
Changes In Account Receivables
0.06
-18.99%
0.08
+71.74%
0.05
+132.86%
-0.14
Change In Inventory
0.03
+200.00%
-0.03
-616.67%
0.01
+400.00%
-0.00
Change In Prepaid Assets
0.12
+160.10%
-0.20
-110.02%
1.98
+236.94%
-1.44
Change In Payables And Accrued Expense
-2.57
-167.87%
3.78
+328.80%
-1.65
-407.25%
0.54
Change In Accrued Expense
-2.22
-154.84%
4.05
+2929.37%
-0.14
-156.52%
0.25
Change In Payable
-0.35
-31.82%
-0.26
+82.52%
-1.51
-629.82%
0.28
Change In Account Payable
-0.35
-31.82%
-0.26
+82.52%
-1.51
-629.82%
0.28
Change In Other Working Capital
—
—
—
—
Change In Other Current Liabilities
-1.00
-137.53%
-0.42
+25.62%
-0.57
-14.81%
-0.49
Investing Cash Flow
-0.04
-100.62%
6.32
+521.35%
-1.50
+85.25%
-10.16
Cash Flow From Continuing Investing Activities
-0.04
-100.62%
6.32
+521.35%
-1.50
+85.25%
-10.16
Net PPE Purchase And Sale
-0.04
-160.00%
-0.01
+95.45%
-0.33
+93.63%
-5.18
Purchase Of PPE
-0.04
-160.00%
-0.01
+95.45%
-0.33
+93.63%
-5.18
Capital Expenditure
-0.04
-160.00%
-0.01
+95.45%
-0.33
+93.63%
-5.18
Net Investment Purchase And Sale
0.00
-100.00%
6.33
+641.57%
-1.17
+76.55%
-4.99
Purchase Of Investment
0.00
+100.00%
-6.17
+0.00%
-6.17
+74.94%
-24.61
Sale Of Investment
0.00
-100.00%
12.50
+150.00%
5.00
-74.53%
19.63
Financing Cash Flow
11.52
+853.30%
-1.53
-103.63%
42.16
+144.44%
17.25
Cash Flow From Continuing Financing Activities
11.52
+853.30%
-1.53
-103.63%
42.16
+144.44%
17.25
Net Issuance Payments Of Debt
1.12
+110.24%
-10.90
-4150.56%
0.27
-95.16%
5.56
Issuance Of Debt
1.50
-84.89%
9.92
+2735.43%
0.35
-93.85%
5.70
Repayment Of Debt
-0.38
+98.16%
-20.82
-25603.70%
-0.08
+40.00%
-0.14
Long Term Debt Issuance
1.50
-84.89%
9.92
+2735.43%
0.35
-93.85%
5.70
Long Term Debt Payments
-0.38
+98.16%
-20.82
-25603.70%
-0.08
+40.00%
-0.14
Net Long Term Debt Issuance
1.12
+110.24%
-10.90
-4150.56%
0.27
-95.16%
5.56
Net Common Stock Issuance
10.40
+12.54%
9.24
-78.04%
42.09
+267.31%
11.46
Proceeds From Stock Option Exercised
0.00
-100.00%
0.12
0.00
-100.00%
0.31
Net Other Financing Charges
—
—
-0.20
-146.91%
-0.08
Changes In Cash
-7.07
+57.27%
-16.54
-257.62%
10.49
+132.87%
-31.93
Effect Of Exchange Rate Changes
0.10
+179.53%
-0.13
-3075.00%
-0.00
+86.67%
-0.03
Beginning Cash Position
12.21
-57.71%
28.88
+57.04%
18.39
-63.47%
50.35
End Cash Position
5.25
-57.04%
12.21
-57.71%
28.88
+57.04%
18.39
Free Cash Flow
-18.59
+12.91%
-21.34
+30.03%
-30.50
+30.98%
-44.19
Interest Paid Supplemental Data
1.04
-60.08%
2.61
-14.58%
3.06
+31.85%
2.32
Change In Income Tax Payable
—
—
—
0.00
Change In Tax Payable
—
—
—
0.00
Common Stock Issuance
10.40
+12.54%
9.24
-78.04%
42.09
+267.31%
11.46
Issuance Of Capital Stock
10.40
+12.54%
9.24
-78.04%
42.09
+267.31%
11.46
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category